secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-04-03T23:59:59+00:00
Accession:  0001104659-25-031713
Event type: other_material
Sentiment:  negative
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics enters ATM equity distribution agreement for up to $8.135M
-------------------------------------------------------------------------------

- Entered Equity Distribution Agreement with Canaccord Genuity LLC on April 3, 2025.
- May sell up to $8,135,000 of common stock via at-the-market offerings under existing shelf registration.
- Canaccord receives up to 3.0% commission on gross proceeds; Company reimburses certain expenses.
- Shares sold through Nasdaq or other trading market at prevailing prices with no minimum price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925031713/0001104659-25-031713-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925031713/tm2511361d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-031713

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer